Eli Lilly & Co. said its next-generation obesity injection, retatrutide, showed no increase in overall heart risk in a recent study [1].
The result is a critical step for the company as it seeks to dispel concerns regarding cardiovascular safety and move the experimental drug toward regulatory approval [1].
Retatrutide has now cleared two additional trials [4]. This progress follows a series of five late-stage trials designed to test the efficacy and safety of the weight-loss treatment [3]. By demonstrating that the drug does not heighten the risk of heart complications, the company removes a significant barrier that often complicates the approval process for metabolic medications.
There are conflicting reports regarding the exact timing of the company's next steps. One report said Eli Lilly plans to file for U.S. FDA approval early next year [1]. However, other reports said the company will file for approval in 2027 [2].
The drug is part of a broader effort by Eli Lilly to expand its portfolio of obesity treatments. Retatrutide represents a new generation of injections aimed at providing more potent weight loss than previous iterations. The successful completion of these trials allows the company to finalize its data package for the FDA.
“Retatrutide showed no increase in overall heart risk in a recent study.”
The absence of cardiovascular risk is a pivotal finding because heart health is a primary safety metric for the FDA when evaluating long-term obesity treatments. If the drug maintains this safety profile while delivering superior weight loss, it could shift the competitive landscape of the obesity market by offering a more potent alternative to existing GLP-1 therapies.
